News | November 09, 2023
Biocon Biologics announces divestment of two non-core branded formulations
Total transaction value of the divestment is Rs. 3,660 million
Total transaction value of the divestment is Rs. 3,660 million
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin's Nagpur facility in India
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
With the establishment of five different precious metals alloy powder production methods
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
RHTC will address a long-standing healthcare access issue for all the local population
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
